<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001915'>Aplastic anemia</z:hpo> (AA) is most frequently due to autoimmune attack on its own stem cells </plain></SENT>
<SENT sid="1" pm="."><plain>Alemtuzumab is a monoclonal antibody which recognizes the CD52 antigen on the surface of T and B cells </plain></SENT>
<SENT sid="2" pm="."><plain>It has proved useful in <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, lymphoproliferative conditions, and <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Based on its immunosuppressive properties, we treated 14 AA patients with alemtuzumab </plain></SENT>
<SENT sid="4" pm="."><plain>Median age was 23 years </plain></SENT>
<SENT sid="5" pm="."><plain>Ten milligrams of alemtuzumab were injected subcutaneously each day for five consecutive days </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> A was also administered orally at a dose of 2 mg/kg every 12 h for 3 months, and then gradually tapered </plain></SENT>
<SENT sid="7" pm="."><plain>Response to alemtuzumab was followed for a median of 20 months </plain></SENT>
<SENT sid="8" pm="."><plain>There were eight responses (57.1%), two complete and six partial </plain></SENT>
<SENT sid="9" pm="."><plain>Whereas six (42.8%) patients were non-responders </plain></SENT>
<SENT sid="10" pm="."><plain>Median complete blood count values on alemtuzumab responders were Hb 13.1 mg/dL, absolute neutrophil count 2.4 x 10(9)/L, and platelets 97.5 x 10(9)/L </plain></SENT>
<SENT sid="11" pm="."><plain>A good response was produced in 57% of AA patients with the administration of alemtuzumab, who lacked a stem cell donor </plain></SENT>
</text></document>